Skip to content

Abstract B068: FYN and other Src family kinases antagonize response to RAS inhibition in pancreatic ductal adenocarcinoma

Sep 2026 · Cancer Research · Vol 86, pp. B068-B068 · 0 citations

TL;DR

These findings identify distinct adaptive pathways orchestrating RAS-dependent versus RAS-independent resistance in PDAC and propose combination strategies for clinical evaluation to enhance KRAS-directed therapy durability.

Abstract

Oncogenic KRAS drives pancreatic ductal adenocarcinoma (PDAC), yet resistance to RAS antagonists limit benefits. To define therapeutic response and resistance mechanisms, we deployed two complementary preclinical PDAC models, including a degron-regulated KRASG12D-dependent transplantation model, and a Kras G12V-driven PDAC mouse model treated with the RAS(ON) multi-selective inhibitor, RMC-7977. KRASG12D degradation provoked RAS-dependent relapse, characterized by compensatory wild-type (WT) RAS upregulation, restored MAPK signaling and proliferation, and a shift towards hybrid cancer cell states. In contrast, RMC-7977 treatment triggered rapid RAS-independent resistance within 7 days, distinguished by suppressed MAPK yet restored proliferation with increased epithelial differentiation, and upregulation of Fyn. Mechanistically, this RAS-independent program converged on an Src-family kinase (SFK)-YAP axis. Antagonism of WT RAS or FYN attenuated resistance; and combining FYN/SFK antagonism with RMC-7977 prevented the uncoupling of MAPK signaling from cell proliferation in the respective Kras G12V PDAC model. Our findings identify distinct adaptive pathways orchestrating RAS-dependent versus RAS-independent resistance in PDAC and propose combination strategies for clinical evaluation to enhance KRAS-directed therapy durability. Hsiu-Chi Ting, Sun Y. Kim, Victoria Gaeth, Juliene Hinds, Astrid Deschenes, Amber N. Habowski, Peyton Smith, Heesang Yoo, Fatim Kouassi, Amanda Jensen, Julia Forte, Steven Portillo, Jonathan Kastan, Nicole M. Sodir, Youngkyu Park, Daniel A. King, Christopher R. Vakoc, Mallika Singh, David A. Tuveson. FYN and other Src family kinases antagonize response to RAS inhibition in pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B068.

View source

Similar papers

Sep 2026

Abstract B070: Adaptive KRAS-MAPK signaling mediates resistance to CD73 blockade in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) remains highly refractory to therapy due to oncogenic KRAS signaling and an immunosuppressive tumor microenvironment. We previously established that CD73 is induced early during pancreatic tumorigenesis, where extracellular adenosine promotes disease progression through ADO...

Khadija Turabi, Shwetapadma Dash, Lincoln N. Strickland et al. · 0 citations
Sep 2026

Abstract PR012: Encoding adaptive mechanisms of resistance to KRAS inhibition in pancreatic cancer

This study defines adaptive resistance mechanisms to KRAS-targeted therapy in PDAC, revealing both cell-state-dependent RTK rewiring and a conserved SFK adaptive signaling axis and provides a mechanistic rationale for either KRAS/pan-RAS or pan-RAS/SFK co-inhibition as strategies to improve responses to KRAS-targeted t...

Qing-Xiang Lin, Bo-Kai Song, C. Sander et al. · 1 citation
Sep 2026

Abstract PR008: EMT-associated focal adhesion signaling mediates resistance to RAS inhibition

Direct inhibition of oncogenic RAS has emerged as a clinically active therapeutic strategy for RAS-addicted cancers, including pancreatic ductal adenocarcinoma (PDAC). However, resistance is likely to limit the durability of therapeutic response, motivating combination strategies that target adaptive survival mechani...

Joshua H. Choe, Kyle J. Seamon, Julien Dilly et al. · 0 citations
Sep 2026

Abstract B050: ERK1 splicing switch triggers lethal hyperactivation and overcomes KRAS inhibitor resistance in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second leading cause of cancer death in the United States by 2040. Oncogenic KRAS, present in ∼90% of PDACs, drives tumor growth through MAPK signaling and ERK1/2 activation. While pan-RAS and mutant-selective KRAS inhibitors can produce initial r...

Luisa F. Escobar-Hoyos, Md Siraj Afjalus, Deanne E. Yugawa et al. · 0 citations
Open access Oct 2026

Targeting Distinct Cell Cycle Nodes Overcomes RAS Inhibitor Resistance.

Activating mutations in KRAS drive pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). Although mutant-selective KRAS inhibitors and pan-RAS inhibitors provide clinical benefits, the development of resistance limits durable responses. Here, transcriptomic and proteomic analyses revealed that...

V. Kumarasamy, Jian-Xin Wang, Edwin H. Yau et al. · 0 citations
Open access Sep 2026

Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1

The efficacy of immune checkpoint blockade (ICB) in lung adenocarcinoma (LUAD) is limited by primary or acquired resistance, especially in genetically defined subsets. We investigated the impact of KRAS/TP53 co-mutation on ICB response. Our analysis reveals that KRAS/TP53 co-mutation is associated with favorable ICB ou...

Xin Zhang, Q. Hao, Wen-Yue Yang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.